FMC-242 / Frontier Medicines - LARVOL DELTA

FMC-242, a highly potent and selective covalent inhibitor of the PI3Ka-RAS interaction that demonstrates improved efficacy and tolerability as monotherapy and in combination with targeted therapies in preclinical models (AACR-NCI-EORTC 2025) - "Inhibition of the PI3Ka-RAS interaction does not affect insulin signaling or blood glucose levels and is well tolerated in vivo. Together, these data demonstrate the promise of FMC-242 as a selective covalent inhibitor of PI3Ka-RAS interaction, with the potential to deliver improved outcomes for patients as a monotherapy and in combination with targeted therapies such as KRAS or RTK inhibitors in the clinic."

Combination therapy • Late-breaking abstract • Monotherapy • Preclinical • Oncology • HER-2 • KRAS